Lynparza Poised To Bring Targeted Therapy To Prostate Cancer

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.

Detailed Phase III results of AstraZeneca PLC and Merck & Co. Inc.'s PARP inhibitor Lynparza (olaparib) impressed at the European Society for Medical Oncology meeting on 30 September. The results showed Lynparza doubled the time to radiographic progression-free survival (rPFS) in men with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed on hormone therapy.

They also showed an improvement in a broader population of men with homologous recombination repair (HRRm) gene mutations, though the...